🔗 Share this article

Given that the United States proceeds with historic revisions to its vaccination schedules, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccines during the pandemic and has zeroed in on alleged fatalities following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Public health authorities were set to announce sweeping revisions to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US at odds with a large portion of the international standard with no evidence for public health gain. This reveal has been pushed back until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the gathering. She was just designated acting director of the FDA’s CDER, the fifth person to head the office this calendar year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing certain childhood vaccine recommendations in the US to become more in line with Denmark, a nation with nationalized medicine and a citizenry about the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccines – usually the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Expertise

The appointee has no obvious background in pharmaceutical research, regulation or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for leading the CDER, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in running a large organization. She has no expertise in drug approvals.”

Previous directors of the center would “understand legal statutes and the underlying principles of drug development”, commented Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led CBER have had.”

This division has an immense portfolio at the FDA, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office authorizes numerous generic medications. There is also a biologic copycat branch, OTC medication office and more, and each of these need to be supervised,” Woodcock explained. “The area you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a significant administrative aspect to the position, which supervises in excess of 5,000 employees. “It’s a massive management job, if you execute it properly,” the former official said.

Response and Disputed Policies

Regarding inquiries about Høeg’s credentials and whether this appointment represents more teamwork among FDA leaders on vaccines, a press secretary stated that the “inquiries rely on incorrect assumptions”.

“Her resume aligns with the functions of her job,” the official stated, citing the period Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day medication authorization process that apparently concerned her former heads. “By what process are these medications being selected for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards less stringent rules of pharmaceuticals, except for vaccines.”

Public Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, Howard have noted. She published a research paper using unverified public submissions to determine the rate of heart inflammation following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the new federal leadership featured changing regulations for novel immunizations and discontinuing “non-essential” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of preventing young men from getting Covid vaccines.

“She is an all-around dogmatist who starts off with her conclusions and works backwards to fit the data in a extremely misleading, fraudulent manner,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg became part of other dissenters, {like|